TickerGuard
Buy Day today: Poor (44) Weak market breadth · no major macro event
HYFT

ImmunoPrecise Antibodies Ltd.

Healthcare · Biotechnology

0.9378$ -5.3% vs. previous close Closing price · As of: Nov 16, 2026

Ownership

Ownership Structure

Who owns ImmunoPrecise Antibodies Ltd. (HYFT)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 89.7% of the shares are freely tradable; institutional investors hold 10.0%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 10.0%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 9.1%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 89.7%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 2.3%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 48Mio.

Largest Shareholders

Institutions

Institutions HYFT
Name Stake (%) Shares Change (%) Date
Ingalls & Snyder LLC 6.44 3,035,479 +4.4 06/30/2026
Susquehanna International Group, LLP 1.11 520,769 -2.5 06/30/2026
Renaissance Technologies Corp 0.45 213,380 -8.2 06/30/2026
BlackRock Inc 0.33 154,411 +0.0 06/30/2026
Marshall Wace Asset Management Ltd 0.29 135,967 +438.6 06/30/2026
Bank of Montreal 0.17 77,947 +11.4 06/30/2026
BMO Capital Markets Corp. 0.17 77,947 +11.4 06/30/2026
Allianz Asset Management AG 0.07 35,000 +0.0 06/30/2026
GSA Capital Partners LLP 0.07 34,525 +0.0 06/30/2026

Funds

Funds HYFT
Name Stake (%) Shares Change (%) Date
iShares Micro-Cap ETF 0.28 131,390 +0.0 10/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: November 16, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?